Prosecution Insights
Last updated: April 19, 2026
Application No. 18/535,599

SINGLE PART BANDAGE AND METHOD FOR A MEDICAL SENSOR

Non-Final OA §102§DP
Filed
Dec 11, 2023
Examiner
FARDANESH, MARJAN
Art Unit
3791
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Covidien LP
OA Round
1 (Non-Final)
72%
Grant Probability
Favorable
1-2
OA Rounds
3y 6m
To Grant
91%
With Interview

Examiner Intelligence

Grants 72% — above average
72%
Career Allow Rate
613 granted / 846 resolved
+2.5% vs TC avg
Strong +18% interview lift
Without
With
+18.5%
Interview Lift
resolved cases with interview
Typical timeline
3y 6m
Avg Prosecution
28 currently pending
Career history
874
Total Applications
across all art units

Statute-Specific Performance

§101
8.8%
-31.2% vs TC avg
§103
29.6%
-10.4% vs TC avg
§102
28.7%
-11.3% vs TC avg
§112
21.8%
-18.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 846 resolved cases

Office Action

§102 §DP
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 21-36 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Hoarau et al. (USPN 7,650,177-previously cited). Regarding claims 21 Hoarau et al. discloses a sensor, comprising: a light-emitting diode (LED); a detector to detect light emitted by the LED; and a bandage, comprising: a first portion of the bandage; a second portion of the bandage; and a releasable liner disposed between the first portion and the second portion to facilitate folding open the first portion and the second portion to enable insertion of at least the LED and the detector between the first portion and the second portion. See the annotated figure below and Col.6 line 44- Col.7 line 25. PNG media_image1.png 392 499 media_image1.png Greyscale Regarding claim 22, the first portion and the second portion fold to close over at least the LED and the detector after the insertion of at least the LED and the detector between the first portion and the second portion (as shown in the figure above the fold line facilitates folding the first and the second portions). Regarding claim 23, Hoarau et al. discloses the releasable liner exposes an adhesive after removal of the releasable liner from the bandage to adhere the LED, the detector, or both to the bandage (Examiner inherently interprets that the adhesive layer shown in the figure above includes a releasable liner to cover the adhesive in order to protect the adhesive). See the annotated figure above and Col.6 line 44- Col.7 line 25. Regarding claim 24, the releasable liner comprises a tab to facilitate peeling the releasable liner from the bandage (See the annotated figure above and Col.6 line 44- Col.7 line 25). Regarding claim 25, the bandage comprises a tab coupled to the first portion to facilitate folding open the first portion and the second portion (as shown in the figure above the tab is configured to folding open the first portion and the second portion). Regarding claim 26, the tab comprises a polyethylene film. Regarding claim 27, the first portion comprises a metalized tape that shields the LED, the detector, or both. Regarding claim 28, the second portion comprises an additional metalized tape with holes that enable the light to pass across the additional metalized tape. Regarding claim 29, the bandage comprises a fold line to facilitate folding open the first portion and the second portion at the fold line. Regarding claim 30, the bandage comprises an additional releasable liner disposed between the first portion and the second portion to facilitate folding open the first portion and the second portion to enable insertion of at least the LED and the detector between the first portion and the second portion. Regarding claim 31, the first portion defines a leaflet to fold away from the second portion. Regarding claim 32, the first portion comprises a backing and a shielding member that define the leaflet to fold away from the second portion. Regarding claim 33, a bandage for a sensor, comprising: a first portion of the bandage; a second portion of the bandage; and a releasable liner disposed between the first portion and the second portion to open the first portion and the second portion for placement of sensor components between the first portion and the second portion. See the annotated figure above and Col.6 line 44- Col.7 line 25. Regarding claim 34, the first portion comprises a metalized tape to fold away from the second portion to open the first portion and the second portion. Regarding claim 35, the second portion comprises an additional metalized tape on a first side of the second portion and an adhesive on a second side of the second portion. Regarding claim 36, an additional releasable liner disposed between the first portion and the second portion, wherein the releasable liner is coupled to the first portion, the additional releasable liner is coupled to the second portion, the releasable liner exposes a first adhesive after removal of the releasable liner for adherence of the sensor components, and the additional releasable liner exposes a second adhesive after removal of the additional releasable liner for adherence of the sensor components. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 21-36 rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-20 of U.S. Patent No. 11872037. Although the claims at issue are not identical, they are not patentably distinct from each other because the claims of the instant application are broader than those of the Patent. As, such, any invention meeting the limitations of the claims of the Patent would necessarily meet those of the instant application as well. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to MARJAN FARDANESH whose telephone number is (571)270-5508. The examiner can normally be reached Monday-Friday 9:00-17:00. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jacqueline Cheng can be reached on (571)272-5596. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MARJAN FARDANESH/Primary Examiner, Art Unit 3791
Read full office action

Prosecution Timeline

Dec 11, 2023
Application Filed
Jan 25, 2024
Response after Non-Final Action
Feb 21, 2026
Non-Final Rejection — §102, §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12594064
DUAL MOVABLE BLADE BIOPSY TOOL WITH STYLET
2y 5m to grant Granted Apr 07, 2026
Patent 12588841
CALIBRATION-FREE PULSE OXIMETRY
2y 5m to grant Granted Mar 31, 2026
Patent 12582313
PHYSIOLOGICAL MONITORING SYSTEM
2y 5m to grant Granted Mar 24, 2026
Patent 12582336
DETECTION DEVICE
2y 5m to grant Granted Mar 24, 2026
Patent 12551147
ANALYTE SENSOR
2y 5m to grant Granted Feb 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
72%
Grant Probability
91%
With Interview (+18.5%)
3y 6m
Median Time to Grant
Low
PTA Risk
Based on 846 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month